Organisms:

  • Typically Enterobacteriacae including Escherichia coli and Klebsiella
  • Enterococcus
  • Patients with catheters are at risk of multi-resistant organisms and a wider range of organisms including:
    • Pseudomonas
    • Staphylococcus aureus
    • Proteus

Investigations:

  • Urine culture in symptomatic patients may help guide antibiotic therapy
  • Urine dipstick tests should not be used in the elderly population as bacteria in the urine is common (and may be protective). Clinical signs and symptoms should be used to identify infection
  • Urine culture is often positive in older patients and does not imply infection if not symptomatic
  • UTI should only be diagnosed

a) when the patient has urinary tract symptoms or
b) when a confused patient has signs of a systemic inflammatory response and no other source of infection or delirium is evident

Lower UTI/cystitis (H@H)

Length of treatment: 3 days in women, 7 days in men

Nitrofurantoin 100mg MR orally every 12 hours

  • Not for systemic symptoms (e.g. fever, shaking, chills, palpitations), upper UTI, or patients with raised inflammatory markers
  • Use alternative drug if suspension required (due to prohibitive cost)
  • If eGFR 30-45 ml/min use with caution for short course. Do not use if eGFR<30 ml/min
  • Be alert to risks of pulmonary and hepatic drug reactions - see MHRA warning 2023

OR

Pivmecillinam initially 400 mg for 1 dose, then 200 mg orally every 8 hours 

(Note: is a penicillin).

 

Alternative, if known trimethoprim susceptible isolate.

Trimethoprim 200mg orally every 12 hours

(see Appendix 1 for dose reduction in renal impairment)

 

Alternative in penicillin allergy and eGFR 10-30ml/min

Fosfomycin 3g STAT dose oral (prescribe as Monuril®) [repeat after 72 hours in men – total of 2 doses].

  • Dose at night after emptying bladder

 

Alternative if unable to use above options

Cefalexin 500mg oral every 12 hours, women 3 days, men 7 days

Note: is a first generation cephalosporin

Pyelonephritis or urinary tract infection with signs of sepsis (H@H)

Length of treatment: 7 days

Gentamicin intravenous: use NHS Lothian online calculator.

  • Review after 48 hours of IV therapy and switch to oral if symptomatic improvement
  • Gentamicin should not be extended for more than 72 hours in H@H patients without advice from an infection specialist, consideration of toxicities and monitoring. (Note this differs from advice for patients in acute care settings where up to 5 days may be given)
  • Oral switch based on MSU result where available [do NOT use nitrofurantoin, pivmecillinam, or fosfomycin]
  • If culture results not available review urine results in previous year; if no trimethoprim resistant isolates then consider co-trimoxazole

 

 

Catheter associated urinary tract infection (CAUTI) (H@H)

Do not use urine dipstick to diagnosis catheter associated urinary tract infection

Urine culture is often positive in catheterised patients; this does not differentiate between colonisation and infection

Catheter associated urinary tract infection is diagnosed clinically

Catheter associated urinary tract infection diagnosis is based on the following:

  • Temperature >38oC (this may be absent in older patients)
  • No evidence of focus of infection elsewhere
  • Any of the following signs or symptoms:
    • Rigor
    • Supra-pubic or flank pain
    • Frank haematuria
    • Delirium

Review the need for the catheter – consider permanent removal

If catheter has been in for >7 days and cannot be permanently removed change the catheter (within 24 hours of starting antibiotics).

Obtain a urine sample before antibiotics are taken.

Take the sample from the catheter via a sampling port (using aseptic technique).

If the catheter has been changed take the sample from the new catheter.

If the catheter has been removed obtain a midstream specimen of urine.

 

Contact Microbiology for advice if gentamicin resistance in urinary isolates within last 6 months.

Gentamicin intravenous as per NHS Lothian online calculator stat dose

AND catheter change

 

Assess need for ongoing oral therapy.

Editorial Information

Author(s): Carol Philip and Naomi Henderson.

Author email(s): Linda.m.Robertson@nhslothian.scot.nhs.uk.

Approved By: AMC meeting